Global Influenza Vaccines Market To Exhibit A Valuation Of USD 6.5 Billion By 2027

January 12, 2022


According to the report titled ‘Global Influenza Vaccines Market 2021 – 2027,’ available with MarketStudyReport, global influenza vaccines market is anticipated to amass a valuation of USD 6.5 billion during 2021-2027
 

Widespread awareness of the disease, the introduction of quadrivalent influenza vaccines, massive recommendation programs by the government for getting immunized against the ailment are factors propelling the growth of global influenza vaccines market.
 

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/3676278/
 

The document incorporates various factors augmenting the growth of the market as well as limitations hampering the overall development during the analysis period. It outlines the opportunities available in the environment that can be used to garner lucrative returns in the coming years.
 

Moreover, a thorough study of total number of people being vaccinated across the globe, along with the latest developments in the field is entailed in the report. As per expert researchers, the count of the vaccinated population against the influenza disease is likely to touch the figure of 500 million by the end of 2027.
 

Taking the research further, a rigorous examination of the geographical scope is also included for a broader perspective of this business sphere. Based on regional spectrum, the market spans across North America (U.S., Canada), Latin America (Brazil), Europe (France, Ireland, Germany, Belgium, Spain, Italy, U.K., Netherlands, Italy, Denmark, Sweden, Poland, Finland), and Asia Pacific (India, China, Australia, New Zealand Japan),
 

Granular analysis of the competitive terrain assesses the prominent players of worldwide influenza vaccines industry, including Pneumagen Limited, Sanofi S.A., Shanghai Institute of Biological Products Co. Ltd., Mylan N.V., FluGen, Inc., AstraZeneca plc, Novavax, Inc., Moderna, Inc., Hualan Biological Engineering, Inc., CSL Limited, BioDiem, Inc., Daiichi Sankyo Company Limited, GlaxoSmithKline (GSK) plc, Medicago, Inc., and Altimmune, Inc. among others.
 

For a better understanding of the stakeholders, aspects like revenue share, current vaccines portfolios, promising vaccines in the clinical development, sales value analysis, and overall performance of the profiled companies is demonstrated in the study of global influenza vaccines market.  It also provides in-depth information on key trends concerning collaboration deals, merger & acquisitions, distribution, and licensing agreement.

Chat with us